Epidermal growth factor receptor inhibition strategies in oncology
PM Harari - Endocrine-related cancer, 2004 - erc.bioscientifica.com
Molecular targeting strategies for cancer therapy are distinct from conventional
chemotherapy and radiotherapy in their potential to provide increased tumor specificity. One …
chemotherapy and radiotherapy in their potential to provide increased tumor specificity. One …
Epidermal growth factor receptor in relation to tumor development: EGFR‐targeted anticancer therapy
I Okamoto - The FEBS journal, 2010 - Wiley Online Library
The discovery that signaling by the epidermal growth factor receptor (EGFR) plays a key role
in tumorigenesis prompted efforts to target this receptor in anticancer therapy. Two different …
in tumorigenesis prompted efforts to target this receptor in anticancer therapy. Two different …
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation
SM Thomas, JR Grandis - Cancer treatment reviews, 2004 - Elsevier
The epidermal growth factor receptor (EGFR) is overexpressed in many solid tumours.
Targeting EGFR is emerging as a potential strategy to incorporate into cancer treatment …
Targeting EGFR is emerging as a potential strategy to incorporate into cancer treatment …
Epidermal growth factor receptor: a promising target in solid tumours
JJ Laskin, AB Sandler - Cancer treatment reviews, 2004 - Elsevier
The epidermal growth factor receptor (EGFR) is expressed in a wide variety of solid tumours.
It has been demonstrated that the EGFR-associated signaling pathway plays an important …
It has been demonstrated that the EGFR-associated signaling pathway plays an important …
Epidermal growth factor receptor inhibitors: coming of age
Background: Agents targeting the epidermal growth factor (EGFR)-mediated signaling
pathway are used in the treatment of various solid tumors, including lung, breast, pancreatic …
pathway are used in the treatment of various solid tumors, including lung, breast, pancreatic …
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR) combining anti-EGFR antibody with tyrosine kinase inhibitor
S Huang, EA Armstrong, S Benavente, P Chinnaiyan… - Cancer research, 2004 - AACR
Molecular inhibition of epidermal growth factor receptor (EGFR/HER1) signaling is under
active investigation as a promising cancer treatment strategy. We examined the potency of …
active investigation as a promising cancer treatment strategy. We examined the potency of …
Clinical implications of the mechanism of epidermal growth factor receptor inhibitors
J Marshall - Cancer, 2006 - Wiley Online Library
Novel therapeutic agents that target the epidermal growth factor receptor (EGFR) constitute
an important addition to the therapeutic armamentarium for the treatment of metastatic …
an important addition to the therapeutic armamentarium for the treatment of metastatic …
Biology of interactions: antiepidermal growth factor receptor agents
PM Harari, GW Allen, JA Bonner - Journal of Clinical Oncology, 2007 - ascopubs.org
Epidermal growth factor receptor (EGFR) signaling inhibition represents a highly promising
arena for the application of molecularly targeted cancer therapies. Evolving from several …
arena for the application of molecularly targeted cancer therapies. Evolving from several …
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
J Baselga, CL Arteaga - Journal of Clinical Oncology, 2005 - ascopubs.org
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB
receptor family that is abnormally activated in many epithelial tumors. The aberrant …
receptor family that is abnormally activated in many epithelial tumors. The aberrant …
[HTML][HTML] Growth factor receptor interplay and resistance in cancer
HE Jones, JMW Gee, IR Hutcheson… - Endocrine-related …, 2006 - erc.bioscientifica.com
Aberrant signalling through the epidermal growth factor receptor (EGFR) plays a major role
in the progression and maintenance of the malignant phenotype and the receptor is …
in the progression and maintenance of the malignant phenotype and the receptor is …